769
Views
0
CrossRef citations to date
0
Altmetric
Themed Issue: Perspectives from Academic Drug Discovery Conference (Cambridge, UK) – Editorials

Unlocking the Potential of Chemical Probes for Methyl-Lysine Reader Proteins

Pages 1831-1833 | Published online: 22 Sep 2015

References

  • Ptashne M . Epigenetics: core misconcept. Proc. Natl Acad. Sci. USA110 (18), 7101–7103 (2013).
  • Arrowsmith CH , BountraC, FishPV, LeeK, SchapiraM. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov.11 (5), 384–400 (2012).
  • Frye SV . The art of the chemical probe. Nat. Chem. Biol.6 (3), 159–161 (2010).
  • Bunnage ME , CheklerELP, JonesLH. Target validation using chemical probes. Nat. Chem. Biol.9 (4), 195–199 (2013).
  • Copeland RA , OlhavaEJ, ScottMP. Targeting epigenetic enzymes for drug discovery. Curr. Opin. Chem. Biol.14 (4), 505–510 (2010).
  • Gao C , HeroldJM, KireevD, WigleT, NorrisJL, FryeS. Biophysical probes reveal a “compromise” nature of the methyl-lysine binding pocket in l3mbtl1. J. Am. Chem. Soc.133 (14), 5357–5362 (2011).
  • Herold JM , WigleTJ, NorrisJLet al. Small-molecule ligands of methyl-lysine binding proteins. J. Med. Chem.54 (7), 2504–2511 (2011).
  • James LI , Barsyte-LovejoyD, ZhongNet al. Discovery of a chemical probe for the l3mbtl3 methyllysine reader domain. Nat. Chem. Biol.9 (3), 184–191 (2013).
  • James LI , KorboukhVK, KrichevskyLet al. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for l3mbtl3. J. Med. Chem.56 (18), 7358–7371 (2013).
  • Perfetti MT , BaughmanBM, DicksonBMet al. Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53bp1. ACS Chem. Biol.10 (4), 1072–1081 (2015).
  • Frye SV , JamesLI. Small-molecule modulation of methyl-lysine-mediated interactions. In : Histone Recognition.ZhouM-M ( Ed.). Springer International Publishing, Switzerland, 243–271 (2015).
  • Workman P , CollinsI. Probing the probes: fitness factors for small molecule tools. Chem. Biol.17 (6), 561–577 (2010).
  • Filippakopoulos P , QiJ, PicaudSet al. Selective inhibition of bet bromodomains. Nature468 (7327), 1067–1073 (2010).
  • Nicodeme E , JeffreyKL, SchaeferUet al. Suppression of inflammation by a synthetic histone mimic. Nature468 (7327), 1119–1123 (2010).
  • Delmore JE , IssaGC, LemieuxMEet al. Bet bromodomain inhibition as a therapeutic strategy to target c-myc. Cell146 (6), 904–917 (2011).
  • Mertz JA , ConeryAR, BryantBMet al. Targeting myc dependence in cancer by inhibiting bet bromodomains. Proc. Natl Acad. Sci. USA108 (40), 16669–16674 (2011).
  • Chung C-W , ToughDF. Bromodomains: a new target class for small molecule drug discovery. Drug Discov. Today Ther. Strateg.9 (2–3), e111–e120 (2012).
  • Loven J , HokeHA, LinCYet al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell153 (2), 320–334 (2013).
  • Jafari R , AlmqvistH, AxelssonHet al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protocols9 (9), 2100–2122 (2014).
  • Arrowsmith CH . The promise and peril of chemical probes. Nat. Chem. Biol.11 (8), 536–541 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.